mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
-0.14 |
0.01 |
mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.093 |
0.01 |
mRNA |
WZ8040 |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.01 |
mRNA |
Repligen 136 |
CTRPv2 |
pan-cancer |
AAC |
0.097 |
0.01 |
mRNA |
Panobinostat |
CCLE |
pan-cancer |
AAC |
0.11 |
0.01 |
mRNA |
neratinib |
CTRPv2 |
pan-cancer |
AAC |
0.093 |
0.01 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.095 |
0.01 |
mRNA |
tacedinaline |
CTRPv2 |
pan-cancer |
AAC |
0.098 |
0.01 |
mRNA |
BRD-K86535717 |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
0.01 |
mRNA |
Talazoparib |
GDSC1000 |
pan-cancer |
AAC |
-0.083 |
0.01 |